Time to add gemtuzumab ozogamicin to intensive chemotherapy for NPM1-mutated acute myeloid leukaemia?

被引：0
|
作者：
Othman, Jad [1 ,2 ,3 ]
Dillon, Richard [1 ,4 ]
机构：
[1] Kings Coll London, Dept Med & Mol Genet, London SE1 9RT, England
[2] Royal North Shore Hosp, Dept Haematol, Sydney, Australia
[3] Univ Sydney, Fac Med & Heath, Sydney, Australia
[4] Guys & St Thomas Hosp NHS Trust, Dept Haematol, London, England
来源：
LANCET HAEMATOLOGY | 2023年 / 10卷 / 07期
关键词：
INDUCTION CHEMOTHERAPY; ADULT PATIENTS; SURVIVAL;
D O I：
10.1016/S2352-3026(23)00092-3
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E478 / E479
页数：2
相关论文
共 50 条
  • [1] Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1-Mutated Acute Myeloid Leukemia
    Doehner, Hartmut
    Weber, Daniela
    Krzykalla, Julia
    Fiedler, Walter
    Kuehn, Michael W. M.
    Schroeder, Thomas
    Mayer, Karin
    Luebbert, Michael
    Wattad, Mohammad
    Goetze, Katharina
    Fransecky, Lars
    Koller, Elisabeth
    Wulf, Gerald
    Schleicher, Jan
    Ringhoffer, Mark
    Greil, Richard
    Hertenstein, Bernd
    Krauter, Juergen
    Martens, Uwe M.
    Nachbaur, David
    Abu Samra, Maisun
    Machherndl-Spandl, Sigrid
    Basara, Nadezda
    Leis, Claudia
    Schrade, Anika
    Kapp-Schwoerer, Silke
    Bullinger, Lars
    Thol, Felicitas R.
    Heuser, Michael
    Paschka, Peter
    Gaidzik, Verena, I
    Saadati, Maral
    Benner, Axel
    Schlenk, Richard F.
    Doehner, Konstanze
    Ganser, Arnold
    BLOOD, 2022, 140 : 2010 - 2013
  • [2] Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial
    Doehner, Hartmut
    Weber, Daniela
    Krzykalla, Julia
    Fiedler, Walter
    Kuehn, Michael W. M.
    Schroeder, Thomas
    Mayer, Karin
    Luebbert, Michael
    Wattad, Mohammed
    Goetze, Katharina
    Fransecky, Lars
    Koller, Elisabeth
    Wulf, Gerald
    Schleicher, Jan
    Ringhoffer, Mark
    Greil, Richard
    Hertenstein, Bernd
    Krauter, Juergen
    Martens, Uwe M.
    Nachbaur, David
    Abu Samra, Maisun
    Machherndl-Spandl, Sigrid
    Basara, Nadezda
    Leis, Claudia
    Schrade, Anika
    Kapp-Schwoerer, Silke
    Cocciardi, Sibylle
    Bullinger, Lars
    Thol, Felicitas
    Heuser, Michael
    Paschka, Peter
    Gaidzik, Verena I.
    Saadati, Maral
    Benner, Axel
    Schlenk, Richard F.
    Doehner, Konstanze
    Ganser, Arnold
    LANCET HAEMATOLOGY, 2023, 10 (07): : e495 - e509
  • [3] Gemtuzumab ozogamicin in acute myeloid leukaemia
    Ravandi, Farhad
    Kantarjian, Hagop
    NATURE REVIEWS CLINICAL ONCOLOGY, 2012, 9 (06) : 310 - 311
  • [4] Gemtuzumab ozogamicin in acute myeloid leukaemia
    Farhad Ravandi
    Hagop Kantarjian
    Nature Reviews Clinical Oncology, 2012, 9 : 310 - 311
  • [5] Dactinomycin in NPM1-Mutated Acute Myeloid Leukemia
    Falini, Brunangelo
    Brunetti, Lorenzo
    Martelli, Maria Paola
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (12): : 1180 - 1182
  • [6] Spotlight on Gemtuzumab Ozogamicin in Acute Myeloid Leukaemia
    Caroline Fenton
    Caroline M. Perry
    BioDrugs, 2006, 20 : 137 - 139
  • [7] Spotlight on gemtuzumab ozogamicin in acute myeloid leukaemia
    Fenton, Caroline
    Perry, Carolbie M.
    BIODRUGS, 2006, 20 (02) : 137 - 139
  • [8] Cytogenetic abnormalities in NPM1-mutated acute myeloid leukemia
    Fu, Weijia
    Huang, Aijie
    Xu, Lili
    Peng, Yanni
    Gao, Lei
    Chen, Li
    Chen, Jie
    Tang, Gusheng
    Yang, Jianmin
    Ni, Xiong
    LEUKEMIA & LYMPHOMA, 2022, 63 (08) : 1956 - 1963
  • [9] The cytological features of NPM1-mutated acute myeloid leukemia
    Bain, Barbara J.
    Heller, Marc
    Toma, Sarmad
    Pavlu, Jiri
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (06) : 560 - 560
  • [10] Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study
    Schlenk, Richard F.
    Paschka, Peter
    Krzykalla, Julia
    Weber, Daniela
    Kapp-Schwoerer, Silke
    Gaidzik, Verena I.
    Leis, Claudia
    Fiedler, Walter
    Kindler, Thomas
    Schroeder, Thomas
    Mayer, Karin
    Luebbert, Michael
    Wattad, Mohammed
    Goetze, Katharina
    Horst, Heinz A.
    Koller, Elisabeth
    Wulf, Gerald
    Schleicher, Jan
    Bentz, Martin
    Greil, Richard
    Hertenstein, Bernd
    Krauter, Juergen
    Martens, Uwe
    Nachbaur, David
    Abu Samra, Maisun
    Girschikofsky, Michael
    Basara, Nadezda
    Benner, Axel
    Thol, Felicitas
    Heuser, Michael
    Ganser, Arnold
    Doehner, Konstanze
    Doehner, Hartmut
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06) : 623 - +
12345